Product Segment Supply Chain Disruptions
Shipping disruptions and delays in supply of materials caused revenue moderation in H2 FY26. Management sees improvement in Q1-Q2 FY27 but the risk of recurring supply chain issues remains.
Qmsmedicalallied · risk themes across the available quarters.
Bear-case history
Shipping disruptions and delays in supply of materials caused revenue moderation in H2 FY26. Management sees improvement in Q1-Q2 FY27 but the risk of recurring supply chain issues remains.
Employee costs increased sharply from ~9.6 crore to 15.2 crore due to hiring 1,200 employees for new patient service programs. These are back-to-back contracted hires, but timing of revenue recognition creates near-term margin pressure.
Analyst raised concerns about online-only pharma distribution players with deep pockets disrupting the market. Management deflected by emphasizing patient management focus but did not provide concrete competitive differentiation strategies.
Management stated camp revenue at ~13 crore for FY26, while the presentation showed 16 crore for 9 months. Management asked to send revised details, suggesting potential data inconsistency that warrants verification.